Cedric Francois - 21 Jan 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Executive Officer, Director
Signature: /s/David Watson, attorney-in-fact for Cedric Francois
Issuer symbol: APLS
Transactions as of: 21 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 25 Jan 2022, 15:58:14 UTC
Previous filing: 10 Feb 2022
Next filing: 01 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+106,244	+8.6%	$0.000000	1,340,487	21 Jan 2022	Direct	F1
holding	APLS	Common Stock						234,411	21 Jan 2022	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+150,672		$0.000000	150,672	21 Jan 2022	Common Stock	150,672	$35.46	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
F2	The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
F3	This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.